Evofem reports record Phexxi net sales of $18.1-$18.3M for FY2023, operating expense down >60%

Evofem Biosciences, Inc.

2023-FY EPS reported $0.05 vs consensus -$0.62 ▲ beat (+108.0%)

Preliminary 2023 net product sales of $18.1-$18.3M, third consecutive year of Phexxi revenue growth.
Total operating expense reduced by more than 60% from 2022 levels; loss from operations improved >75%.
Net product sales exceeded sales and marketing expense for 2023, key milestone.
Definitive agreement to be acquired by Aditxt (ADTX) remains on track for mid-2024 close.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Evofem Biosciences, Inc. reported fiscal year ended December 31, 2023 results: revenue preliminary net product sales in the range of $18.1 to $18.3 million.

Period: fiscal year ended December 31, 2023
Revenue: preliminary net product sales in the range of $18.1 to $18.3 million
Result: preliminary results

Exact text from the filing

contraceptive gel, and the Company’s lowest total operating expenses since becoming a commercial stage company in 2020. ● Achieved preliminary net product sales in the range of $18.1 to $18.3 million in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023. ● Company reached a key milestone

View on SEC.gov

Browse all earnings releases →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-004575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.